Literature DB >> 15700136

Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha.

P Olesen1, T Ledet, L M Rasmussen.   

Abstract

AIMS/HYPOTHESIS: Extracellular matrix modifications and linear medial calcifications are elements of diabetic macroangiopathy. We hypothesised that the bone-related protein osteoprotegerin (OPG) may occur in altered amounts in the arterial wall in diabetes, putatively associated with altered synthesis from vascular cells.
METHODS: The amount of OPG in the thoracic aorta, obtained at autopsy from 21 diabetic and 42 sex- and age-matched controls, was measured in tissue extracts by an ELISA. The production of OPG was estimated in conditioned media by an ELISA, and OPG mRNA was estimated by RT-PCR in vascular cells grown in vitro.
RESULTS: The content of OPG was increased in tunica media samples from diabetic individuals. No differences between diabetic and non-diabetic subjects were observed in tunica intima. Human vascular smooth muscle cells (HVSMCs) produced approximately 30 times more OPG than human umbilical vein endothelial cells. The OPG production into the medium decreased dose- and time-dependently after insulin treatment (maximal effect approximately 60% of control) in HVSMCs, whereas TNF-alpha supplement gave rise to increased OPG synthesis in a time- and dose-dependent manner (maximal effect approximately 200% of control). Similar effects on OPG mRNA expression were observed. Addition of growth hormone (10 ng/ml) or extra glucose (25 mmol/l) to the growth medium had no effect. CONCLUSIONS/
INTERPRETATION: Increased OPG concentrations in the arterial wall in diabetes may be part of generalised matrix alterations, putatively related to the development of vascular calcifications. Altered arterial OPG content may be a consequence of the effects of hormones and cytokines, like insulin and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700136     DOI: 10.1007/s00125-004-1652-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

1.  Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus.

Authors:  S Lehto; L Niskanen; M Suhonen; T Rönnemaa; M Laakso
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-08       Impact factor: 8.311

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

Authors:  P A Price; H H June; J R Buckley; M K Williamson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

4.  Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

Authors:  U M Malyankar; M Scatena; K L Suchland; T J Yun; E A Clark; C M Giachelli
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 5.  Endothelial dysfunction in diabetes.

Authors:  A S De Vriese; T J Verbeuren; J Van de Voorde; N H Lameire; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Increased aortic stiffness in patients with type 1 (insulin-dependent) diabetes mellitus.

Authors:  H Oxlund; L M Rasmussen; T T Andreassen; L Heickendorff
Journal:  Diabetologia       Date:  1989-10       Impact factor: 10.122

7.  Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus.

Authors:  J Nilsson; S Jovinge; A Niemann; R Reneland; H Lithell
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-08       Impact factor: 8.311

8.  Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects.

Authors:  M J Young; J E Adams; G F Anderson; A J Boulton; P R Cavanagh
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

9.  Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis.

Authors:  M Takemoto; K Yokote; M Nishimura; T Shigematsu; T Hasegawa; S Kon; T Uede; T Matsumoto; Y Saito; S Mori
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-03       Impact factor: 8.311

10.  Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo.

Authors:  Mei Y Speer; Marc D McKee; Robert E Guldberg; Lucy Liaw; Hsueh-Ying Yang; Elyse Tung; Gerard Karsenty; Cecilia M Giachelli
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  39 in total

1.  Biomarkers of vascular calcification and mortality in patients with ESRD.

Authors:  Julia J Scialla; W H Linda Kao; Ciprian Crainiceanu; Stephen M Sozio; Pooja C Oberai; Tariq Shafi; Josef Coresh; Neil R Powe; Laura C Plantinga; Bernard G Jaar; Rulan S Parekh
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

2.  An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Authors:  Paola Secchiero; Federica Corallini; Assunta Pandolfi; Agostino Consoli; Riccardo Candido; Bruno Fabris; Claudio Celeghini; Silvano Capitani; Giorgio Zauli
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

3.  Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Authors:  Kirsten Q T Nguyen; Ping Olesen; Thomas Ledet; Lars Melholt Rasmussen
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

4.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

5.  Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.

Authors:  Janine L Oliver; Matthew P Alexander; Allison G Norrod; Irene M Mullins; David W Mullins
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-11       Impact factor: 4.693

6.  Osteoprotegerin and mortality in type 2 diabetic patients.

Authors:  Henrik Reinhard; Maria Lajer; Mari-Anne Gall; Lise Tarnow; Hans-Henrik Parving; Lars M Rasmussen; Peter Rossing
Journal:  Diabetes Care       Date:  2010-10-07       Impact factor: 19.112

7.  Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.

Authors:  Giorgio Zauli; Barbara Toffoli; Maria Grazia di Iasio; Claudio Celeghini; Bruno Fabris; Paola Secchiero
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

Review 8.  Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily.

Authors:  Allan Flyvbjerg
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

9.  Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects.

Authors:  A Esteghamati; A Arefzadeh; A Zandieh; M Salehi Sadaghiani; S Noshad; M Nakhjavani
Journal:  J Endocrinol Invest       Date:  2013 Jul-Aug       Impact factor: 4.256

Review 10.  Medial arterial calcification in diabetes and its relationship to neuropathy.

Authors:  W J Jeffcoate; L M Rasmussen; L C Hofbauer; F L Game
Journal:  Diabetologia       Date:  2009-09-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.